Drug intelligence / Profile preview

SteriLid

Development stage: Unknown
Lead developer: Akorn Holdings
Modality: Small Molecules
Administration: Topical

Overview

SteriLid (specifically SteriLid Antimicrobial) is an over-the-counter antimicrobial eyelid cleanser and facial wash containing 0.01% hypochlorous acid. Developed under the TheraTears brand (currently owned by Prestige Consumer Healthcare), it is designed to manage ocular surface conditions such as dry eye disease, blepharitis, and meibomian gland dysfunction. The product works by effectively removing bacteria, debris, and excess oils from the eyelids and eyelashes, which helps to alleviate burning, irritation, and discomfort. It features a pH-balanced, soap-free, and no-rinse spray formulation that is gentle on the sensitive skin surrounding the eyes.

Brand names: SteriLidTheraTears SteriLidSteriLid Antimicrobial
Other names: hypochlorous acid 0.01%

Beyond the preview

Go deeper on SteriLid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SteriLid.

Explore the full profile